嵌合型猪圆环病毒（PCV1-2）灭活苗对商品猪免疫保护效力的研究

doi:10.11843/j.issn.0366-6964.2013.12.015

Abstract

Abstract:

In this study, Dulac cells were electroporated with the recombinant plasmid pSK-dPCV1-2 constructed in our laboratory to obtain chimeric PCV1-2 virus by passage cultures. The inactivated vaccine of chimeric PCV1-2 virus emulsified with ISA 206 VG adjuvant was vaccinated commercial pigs to evaluate its protective efficacy against PCV2 infection. Twenty 42-day-old conventional pigs were randomly assigned to four groups of five pigs each, and other two pigs served as healthy control. The immune efficacy was evaluated by detecting indirect immunofluorescent assay （IFA）antibody titers, neutralizing antibody titers, growth parameters, viremia post-challenge, gross pathology and histopathology. By 35 days post-vaccination (DPV), all vaccinated pigs had seroconversion to antibody against PCV2 and developed high IFA antibody titers and neutralizing antibody titers at 1/15-1/20. In growth parameters, the average daily weight gain (ADWG) was increased in three immunized groups and the mock group, but there were no gains in challenge control group. Comparison of ADWG of vaccinated pigs with that of challenge pigs revealed statistically significant difference between them (P＜0.05). By 21 days post-challenge, gross and microscopic lesions of lymph nodes and lungs in non-vaccinated but challenged pigs were significantly more severe than those found in vaccinated groups. There were multinucleated giant cells, a number of eosinophilia and lymphocyte depletion in lymph nodes in non-vaccinated but challenged pigs. There were no multinucleated giant cells and less lymphocyte depletion in vaccinated pigs.The log10 of PCV2 viral copy loads detected in lymph nodes in non-vaccinated but challenged pigs were 5.566±0.432, in vaccinated pigs with 10^4.0, 10^5.0, 10^6.0 TCID₅₀·mL^－1were 4.469±1.023, 4.434±0.716，3.521±0.958, respectively. Comparison between pigs vaccinated with 10^5.0, 10^6.0 TCID₅₀·mL^－1and challenging only pigs, the differences were significant (P＜0.05), but there were no clinical syndrome during the whole experiment period. The results illuminated that the inactivated chimeric PCV1-2 could induce protective immunity against PCV2b/1B/Jiangsu/Jingjiang/2012/11/08 infection effectively.

CLC Number:

WANG Zheng-liang, ZHOU Jin-zhu, WANG Xiao-bo, LI Ji-zong, GAO Xing, YU Tian-qi, GAO Song. Chimeric PCV1-2 Inactivation Vaccine Evaluated in Commercial Pigs for Its Protective Efficacy against PCV2 Infection[J]. ACTA VETERINARIA ET ZOOTECHNICA SINICA, 2013, 44(12): 1961-1969.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://www.xmsyxb.com/EN/10.11843/j.issn.0366-6964.2013.12.015

https://www.xmsyxb.com/EN/Y2013/V44/I12/1961

References

［1］BAEKBO P, KRISTENSEN C S, LARSEN L E. Porcine circovirus diseases: A review of PMWS［J］. Transbound Emerg Dis，2012，59(1)：60-67.

［2］刘金鑫，孙梦娇，陈磊，等.猪圆环病毒研究进展［J］.动物医学进展, 2012, 33(2):94-97.

［3］OLVERA A, CORTEY M, SEGALÉS J. Molecular evolution of porcine circovirus type 2 genomes: Phylogeny and clonality ［J］. J Virol，2007，7(2)：175-185.

［4］BEACH N M, RAMAMOORTHY S, OPRIESSNIG T, et al. Novel chimeric porcine circovirus (PCV) with the capsid gene of the emerging PCV2b subtype cloned in the genomic backbone of the non-pathogenic PCV1 is attenuated in vivo and induces protective and cross-protective immunity against PCV2b and PCV2a subtypes in pigs［J］. Vaccine, 2010，29(2)：221-232.

［5］ALLAN G M, ELLIS J A. Porcine circoviruses: A review［J］. J Vet Diagn Invest，2000，12(1)：3-14.

［6］MANKERTZ A, DOMINGO M, FOLCH J M, et al. Characterisation of PCV-2 isolates from Spain, Germany and France［J］. Virus Res，2000，66(1)：65-77.

［7］AWAGITGUL P, MOROZOV I, BOLIN S R, et al. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein［J］. Gen Virol，2000，81(Pt 9)：2281-2287.

［8］MANKERTZ A, MANKERTZ J, WOLF K, et al. Identification of a protein essential for replication of porcine circovirus［J］. Gen Virol, 1998, 79(Pt 2)：381-384.

［9］CHEUNG A K. The essential and nonessential transcription units for viral protein synthesis and DNA replication of porcine circovirus type 2［J］.J Virol，2003，313(2)：452-459.

［10］CHEUNG A K. Transcriptional analysis of porcine circovirus type 2 ［J］.J Virol，2003，305(1)：168-180.

［11］王一平，郭龙军，唐青海，等.猪圆环病毒2型疫苗的研究进展［J］.畜牧兽医学报，2012， 43(9):1337-1345.

［12］LYOO K, JOO H, CALDWELL B, et al. Comparative efficacy of three commercial PCV2 vaccines in conventionally reared pigs［J］. Vet J，2011，189(1):58-62.

［13］宋益，朱丽娜，高崧，等.嵌合型猪圆环病毒2型感染性DNA克隆的构建及其免疫原性研究［J］.微生物学报，2008，48（9）:1234-1240.

［14］FENAUX M, OPRIESSNIG T, HALBUR P G, et al. Immunogenicity and pathogenicity of chimeric infectious DNA clones of pathogenic porine circovirus type 2(PCV2) and nonpathogenic PCV1 in weaning pigs［J］. J Virol，2003，77(20)：11232-11243.

［15］樊晶.猪圆环病毒2型SYBR Green I 荧光定量PCR检测方法的建立和嵌合型PCV1-2活病毒疫苗及其灭活制剂对PCV2低母源抗体猪的免疫保护研究［D］.扬州：扬州大学，2009.

［16］芦银华，谭国蕾.应用间接免疫荧光试验检测猪圆环病毒抗体［J］.中国兽医科技，2002，32(8):19-20.

［17］REED L J, MUENCH H. A simple method of estimating fifty percent endpionts［J］. Am J Epidemiol，1938，27(3)：493-497.

［18］殷震，刘景华.动物病毒学［M］.北京：科学出版社，1997:336-340.

［19］LIU X J, WANG X B, SONG Y, et al. A candidate inactivated chimeric vaccine PCV1-2 evaluated in conventional pigs for its protective efficacy against PCV2 infection［J］. Microbiol Immunol，2011，55(4)：254-266.

［20］KRAKOWKA S, ALLAN G M, ELLIS J A, et al. A nine-base nucleotide sequence in the porcine circovirus type 2 (PCV2) nucleocapsid gene determines viral replication and virulence［J］. Virus Res，2012，164 (1-2)：90-99.

［21］GUO L J, LU Y H, HUANG L P, et al. First construction of infectious clone for newly emerging mutation porcine circovirus type 2(PCV2) followed by comparison with PCV2a and PCV2b genotypes in biological characteristics in vitro［J］. Virol J，2011，8：291-301.

［22］OPRIESSNIG T, PATTERSON A R , MADSON D M,et al. Comparison of efficacy of commercial one dose and two dose PCV2 vaccines using a mixed PRRSV-PCV2-SIV clinical infection model 2-3-months post vaccination［J］.Vaccine，2009，27(7)：1002-1007.

［23］徐磊，宁蓬勃，郭抗抗，等.猪圆环病毒2型疫苗研究进展［J］.动物医学进展，2012，33（10）：64-70.

［24］XIAO C T , HALBUR F G, OPRIESSNIG T. Complete genome sequence of a novel porcine circovirus type 2b variant present in cases of vaccine failures in the United States［J］.J Virol，2012，86(22)：12469.

［25］FORT M, SIBILA M, PEREZ E, et al. One dose of a porcine circovirus 2 (PCV2) sub-unit vaccine administered to 3-week-old conventional piglets elicits cell-mediated immunity and significantly reduces PCV2 viremia in an experimental model［J］. Vaccine，2009，27(30)：4031-4037.

［26］KRAKOWKA S, ELLIS J A, MCNEILLY F, et al. Activation of the immune system is the pivotal event in the production of wasting disease in pigs infected with porcine circovirus-2(PCV2)［J］. Vet Pathol，2001，38(1)：31-42.

［27］王先炜，姜平，韦显凯，等.免疫刺激商品断奶仔猪复制多系统衰竭综合征(PMWS) ［J］.畜牧兽医学报，2008，39(1)：66-71.

Chimeric PCV1-2 Inactivation Vaccine Evaluated in Commercial Pigs for Its Protective Efficacy against PCV2 Infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments